Evidence for the use of intravenous immunoglobulins--a review of the literature.
Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel of immunologists and internists with experience in IVIg therapy reviewed the medical literature for published data concerning treatment with IVIg. The quality of evidence was assessed, and a summary of the available relevant literature in each disease was given. To our knowledge, this is the first all-inclusive comprehensive review, developed to assist the clinician when considering the use of IVIg in autoimmune diseases, immune deficiencies, and other conditions.
Kivity
Shaye
S
Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.
Katz
Uriel
U
Daniel
Natalie
N
Nussinovitch
Udi
U
Papageorgiou
Neophytos
N
Shoenfeld
Yehuda
Y
D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy* / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use*
D016756:Immunoglobulins, Intravenous